Navigation Links
Lab research may one day lead to cancer treatment using patient's own immune cells

A new line of developing research is underway that hopes to use a patient's own immune cells to fight cancer. The field, known as adoptive immunotherapy, is a specialty procedure performed in only a handful of institutions, which may one day include University Hospitals Case Medical Center.

Julian A. Kim, M.D., chief of surgical oncology at UH Ireland Cancer Center, has received a $660,000 grant from the National Institutes of Health for a five-year study that hopes to lead to new treatments using a set of immune cells, called T cells, to fight skin cancer (melanoma) and breast cancer. The research project is called "Molecular studies of T cell clones for adoptive therapy."

The pre-clinical trial, which means it will be used only in human tissues in the laboratory at this stage, will focus on identifying and harvesting T cells within the lymph nodes of patients, activating these T cells and growing them in culture in the laboratory over one to two weeks. The T cells are activated with molecular agents called interleukin-2 and anti-CD3 antibody (OKT3).

It is hoped that results from this research could lead to a safety study, called a Phase I study, in humans using this process. This pre-clinical research will help researchers learn how to most effectively select and obtain the T cells for this form of therapy. In future use with humans, the cells would be grown in the cell processing facility located in the Iris S. and Bert L. Wolstein Research Building, which opened in 2003. The activated T cells would be reinfused into the bloodstream of the same patient to train their immune system to fight the cancer.

According to Kim, the Phase I study would involve about 20 patients and would open in about five years. "If these trials prove successful, a similar approach could be developed in patients with other types of cancer as well," said Kim.


'"/>

Source:University Hospitals of Cleveland


Page: 1

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: